Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab

Shoumariyeh, Khalid; Jung, Johannes; Rassner, Michael; Dold, Sandra Maria; Riebl, Veronika; Pantić, Milena; Herget, Georg W.; Marks, Reinhard; Lübbert, Michael; Wäsch, Ralph; Engelhardt, Monika

doi:10.1007/s00277-021-04490-3

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the development of therapeutic antibodies such as daratumumab, isatuximab, or elotuzumab, MFI analysis of different antigens may play an important role in future MM treatment decisions (12). We were able to show that there are differences in MFI phenotypes between MM samples, precursor diseases (MGUS/SMM), and patients under treatment, primarily in aPC antigen expression rather than in nPC (Figures 1 and 2, Supplementary Figure S3).…”

Section: Discussionmentioning

confidence: 88%

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

ObjectiveIn clinical trials (CTs), the assessment of minimal residual disease (MRD) has proven to have prognostic value for multiple myeloma (MM) patients. Multiparameter flow cytometry (MFC) and next-generation sequencing are currently used in CTs as effective tools for outcome prediction. We have previously described 6- and 8-color MFC panels with and without kappa/lambda, which were equally reliable in detecting aberrant plasma cells (aPC) in myeloma bone marrow (BM) specimens. This follow-up study a) established a highly sensitive single-tube 10-color MFC panel for MRD detection in myeloma samples carrying different disease burden (monoclonal gammopathy of unknown significance (MGUS), smoldering multiple myeloma (SMM), MM), b) evaluated additional, rarely used markers included in this panel, and c) assessed MRD levels and the predictive value in apheresis vs. BM samples of MM patients undergoing autologous stem cell transplantation (ASCT).Methods + ResultsThe 10-color MFC was performed in BM and apheresis samples of 128 MM and pre-MM (MGUS/SMM) patients. The markers CD28, CD200, CD19, and CD117 underwent closer examination. The analysis revealed distinct differences in these antigens between MM, MGUS/SMM, and patients under treatment. In apheresis samples, the 10-color panel determined MRD negativity in 44% of patients. Absence of aPC in apheresis corresponded with disease burden, cytogenetics, and response to induction. It also determined MRD negativity in BM samples after ASCT and was associated with improved progression-free survival.ConclusionThese results highlight the significance of the evaluation of both BM and apheresis samples with a novel highly sensitive 10-color MFC panel.

show abstract

Section: Discussionmentioning

confidence: 88%

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Multiple myeloma (MM) and acute myeloid leukemia (AML) are two different clonal malignant hematological diseases, and their correlation is often described as secondary acute myeloid leukemia after treatment for multiple myeloma [1][2] . However, it is a rare coincidence that AML and MM are diagnosed simultaneously in patients without a history of malignant diseases and special treatment.…”

Section: Introductionmentioning

confidence: 99%

A case of newly diagnosed acute myeloid leukemia with multiple myeloma: challenges in diagnosis and treatment

Li,

Liu,

Liu

2024

Preprint

View full text Add to dashboard Cite

Background: It is a rare coincidence that acute myeloid leukemia and multiple myeloma are diagnosed simultaneously in patients without a history of malignant diseases and special treatment. The pathogenesis, differential diagnosis, and treatment of these patients are still unclear, and currently they are mainly evaluated based on the specific situation of MICM classification. Case report: An 81 year old male with a 2-year history of hypertension was admitted to the hospital for treatment due to recurrent chest tightness and pain for 3 years, which worsened for 1 day. During physical examination, there is obvious chest tightness when lying flat, with general limited mobility, anemic appearance, visible bleeding points on the skin and mucosa, no fever, no liver, spleen, or lymph node enlargement. Bone marrow morphology examination showed active bone marrow hyperplasia, with 28% of primitive cells and weakly positive peroxidase staining; The proportion of plasma cells significantly increased, accounting for 15%; The mature red blood cells are arranged in a prominent shape. At the same time, flow cytometry and bone marrow biopsy revealed two different abnormal cell populations, with 42% being primitive myeloid cells and 10% being abnormally proliferating plasma cells. Serum M protein was detected by serum electrophoresis and immunofixation electrophoresis, and specific reaction precipitation bands were observed with anti IgG and anti LAM. The diagnosis was acute myeloid leukemia with multiple myeloma, and there was no history of malignant disease or special treatment. Treatment and outcome: The patient initially received BCL inhibitor Venetoclax and demethylated drug Azarcytidine for the treatment of acute myeloid leukemia. Subsequently, due to severe cardiac insufficiency caused by coronary atherosclerotic heart disease, the patient could not tolerate the follow-up treatment, and was automatically discharged to the local hospital for life support treatment. Discussion: In the clinical process of diagnosing and treating hematological diseases, it is rare for these two different types of clonal malignant hematological diseases to occur simultaneously. Patient based prospective studies and case series are needed to guide diagnosis and treatment strategies.

show abstract

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab

Cited by 2 publications

References 12 publications

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients

Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients

A case of newly diagnosed acute myeloid leukemia with multiple myeloma: challenges in diagnosis and treatment

Contact Info

Product

Resources

About